VivoSeq
Oncology

Gynecologic Cancer

2

Pipeline Programs

10

Active Trials

5

Companies Involved

Gynecologic Cancer is an early-stage landscape with 2 programs across 5 companies. The most active players are Teva, Azurity Pharmaceuticals, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

78/100

Attrition Rate

10/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 100% of 2 pipeline programs.

Trial Status

21

clinical trials

Recruiting8 · 38%
Completed7 · 33%
Not yet recruiting2 · 10%
Unknown status2 · 10%
Withdrawn1 · 5%
Terminated1 · 5%

Trial Activity

21 trials

Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy
Completed··Phase 3·NCT01435200·64 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)